Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $56.50.

Several research analysts have issued reports on ESTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a report on Wednesday, October 8th. Wall Street Zen raised Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Canaccord Genuity Group began coverage on Establishment Labs in a report on Wednesday, August 20th. They set a “buy” rating and a $60.00 price objective for the company. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Finally, Mizuho increased their price objective on Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th.

Establishment Labs Price Performance

Establishment Labs stock opened at $50.90 on Friday. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $54.06. The stock has a market capitalization of $1.47 billion, a P/E ratio of -16.69 and a beta of 0.85. The stock has a fifty day moving average of $42.44 and a 200-day moving average of $39.36.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The firm had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.80 million. During the same quarter in the prior year, the firm earned ($0.62) EPS. The company’s revenue was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Establishment Labs by 5.2% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock worth $257,000 after buying an additional 300 shares during the period. Raymond James Financial Inc. increased its holdings in shares of Establishment Labs by 0.4% in the first quarter. Raymond James Financial Inc. now owns 119,752 shares of the company’s stock worth $4,886,000 after buying an additional 491 shares during the period. Swiss National Bank increased its holdings in shares of Establishment Labs by 1.3% in the first quarter. Swiss National Bank now owns 39,000 shares of the company’s stock worth $1,591,000 after buying an additional 500 shares during the period. Finally, CWM LLC increased its holdings in shares of Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after buying an additional 686 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.